EVONIK INDUSTRIES AG

Explore how BASF’s non‑binding offer could reshape the German specialty‑chemicals sector, with potential €300 m synergy and a premium for Evonik.

Short‑sale alerts: Multiple asset managers bet against Evonik Industries AG, signaling growing investor skepticism amid volatile stock performance.

Evonik raises 2026 revenue outlook to €2‑2.2 bn after a surprisingly strong Q2, driven by higher volumes, better pricing, and cost‑control—showing resilience amid global supply‑chain turbulence.

Evonik Industries AG: Q1 earnings dip from forex; management projects a cautious Q2 rebound amid geopolitical market pressure, urging investors to weigh volatility against strong fundamentals.

Evonik Industries AG leverages geopolitical shifts to boost margins and diversify into booming 3D‑printing and silicon tetrachloride markets, offering investors strategic growth amid volatility.

Evonik Industries surges as Goldman Sachs boosts European chemical outlook – new earnings‑linked dividend plan balances short‑term gains with long‑term shareholder value.

Evonik Industries faces a 35 % dividend cut after JPMorgan’s downgrade, as liquidity concerns clash with China growth, raising investor worry over future payouts.

Evonik Industries’ third earnings warning in 2025 sends the German specialty‑chemistry firm into a record low, sparking doubts about its future growth and investor prospects.

Evonik Industries AG, a German specialty chemicals manufacturer, is navigating a challenging economic landscape with cautious financial maneuvers and strategic adjustments in response to global economic headwinds.